Breaking News Instant updates and real-time market news.

SDRL

Seadrill

$21.88

-0.12 (-0.55%)

, TRXC

TransEnterix

$4.45

0.01 (0.23%)

08:45
07/13/18
07/13
08:45
07/13/18
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Seadrill (SDRL) 381.30% +83.58, TransEnterix (TRXC) 55.55% +0.80, KKR (KKR) 0.74% +0.33, Pfizer (PFE) 0.41% +0.16, Yamana Gold (AUY) 0.59% +0.14, Tesla (TSLA) 1.82% +0.01, and SPDR S&P Homebuilders (XHB) 1.19% +0.01.

SDRL

Seadrill

$21.88

-0.12 (-0.55%)

TRXC

TransEnterix

$4.45

0.01 (0.23%)

KKR

KKR

$26.60

0.29 (1.10%)

PFE

Pfizer

$37.52

0.2 (0.54%)

AUY

Yamana Gold

$2.90

-0.01 (-0.34%)

TSLA

Tesla

$316.75

-1.55 (-0.49%)

XHB

SPDR Homebuilders

$40.49

0.14 (0.35%)

  • 28

    Jul

  • 22

    Aug

  • 10

    Sep

  • 01

    Oct

SDRL Seadrill
$21.88

-0.12 (-0.55%)

06/01/18
GHSC
06/01/18
UPGRADE
Target $18
GHSC
Buy
Ship Finance upgraded to Buy from Neutral at Seaport Global
Seaport Global analyst Magnus Fyhr upgraded Ship Finance (SFL) to Buy with a $18 price target saying risk/reward is increasingly attractive with several potential catalysts developing over the next few months, combined with the Seadrill (SDRL) restructuring already reflected in estimates. Fyhr said the company has ample dry powder to pursue accretive acquisitions and the current backlog provides cash flow visibility and dividend support.
TRXC TransEnterix
$4.45

0.01 (0.23%)

06/28/18
BTIG
06/28/18
DOWNGRADE
BTIG
Neutral
TransEnterix downgraded to Neutral from Buy at BTIG
BTIG analyst Sean Lavin downgraded TransEnterix to Neutral citing the "rapid" rise in shares.
05/29/18
05/29/18
DOWNGRADE
Target $4

Neutral
TransEnterix downgraded to Neutral with $4 price target at Ladenburg
As previously reported, Ladenburg analyst Jeffrey Cohen downgraded TransEnterix to Neutral from Buy citing valuation with the stock having rallied after the company received FDA approval for expanded indications that now mean the Senhance system is approved for the most commonly performed surgeries in more than 95% of hospitals nationally. Cohen raised his price target for TransEnterix to $4 from $3.50.
05/29/18
LTCO
05/29/18
DOWNGRADE
LTCO
Neutral
TransEnterix downgraded to Neutral from Buy at Ladenburg
05/29/18
STFL
05/29/18
NO CHANGE
Target $4
STFL
Buy
TransEnterix new indications double Senhance's procedure base, says Stifel
Stifel analyst Rick Wise said the FDA approval for TransEnterix to market its Senhance robotic surgical system for laparoscopic inguinal hernia and gallbladder removal came slightly earlier than expected and nearly doubles Senhance's procedure base to 3 million procedures annually. While Wise is not increasing his projections, he thinks the new "critical mass" of indications could accelerate TransEnterix's commercial adoption trajectory over time, he tells investors. The analyst keeps a Buy rating and $4 price target on TransEnterix shares.
KKR KKR
$26.60

0.29 (1.10%)

07/10/18
JMPS
07/10/18
NO CHANGE
Target $33
JMPS
Outperform
KKR price target raised to $33 at JMP Securities after 'impressive' analyst day
JMP Securities analyst Devin Ryan said KKR's investor day was "impressive" and made a compelling pitch for existing and new investors. The recurring themes were that growth opportunities abound, management views the business as at an "inflection" with even more excitement about the future, and the company is focused on simplifying its story and providing more transparency. Following the event, he increased his price target on KKR shares to $33 from $27 and maintains his Outperform rating on the stock.
07/10/18
SBSH
07/10/18
NO CHANGE
Target $31
SBSH
Buy
KKR price target raised to $31 from $28 at Citi
Citi analyst William Katz raised his price target for KKR to $31 and keeps a Buy rating on the shares following the company's investor day. The analyst believes KKR's conversion to a corporation has created a "favorable feedback loop for the sector."
07/10/18
WELS
07/10/18
NO CHANGE
Target $30
WELS
Outperform
KKR price target raised to $30 from $25 at Wells Fargo
Wells Fargo analyst Christopher Harris raised his price target for KKR to $30 from $25 after attending the company's Investor Day and as he believes the outlook appears to remain quite promising. The analyst reiterates an Outperform rating on the shares.
06/27/18
RHCO
06/27/18
NO CHANGE
Target $30
RHCO
Buy
Web.com price target raised to $30 from $24 at SunTrust
SunTrust analyst Naved Khan raised his price target on Web.com to $30, maintaining his view that the company's agreed acquisition by Siris Capital at $25 per share could generate interest from other potential buyers. Among the potential acquirers, the analyst lists Silver Lake, KKR (KKR), Vector Capital, and GoDaddy (GDDY).
PFE Pfizer
$37.52

0.2 (0.54%)

07/11/18
ARGS
07/11/18
NO CHANGE
ARGS
Hold
Pfizer valuation is appropriate, says Argus
Argus analyst David Toung kept his Hold rating on Pfizer, saying the company's valuation at 12.2-times his expected FY19 earnings - below the 12.4-times peer group average for pharmaceutical stocks - is appropriate after its revenue growth slowed in Q1. The analyst notes that higher sales from Eliquis, Ibrance, and Xejanz are being offset by declining sales of drugs faced with a loss of market exclusivity, adding that he remains concerned about competition for Pfizer's key products.
07/11/18
NEED
07/11/18
UPGRADE
Target $5
NEED
Buy
Scynexis upgraded to Buy at Needham after positive phase 2b data for SCY-078
As reported earlier, Needham analyst Alan Carr upgraded Scynexis (SCYX) to Buy from Hold with a price target of $5 after the company's positive Phase 2b trial results of oral SCY-078 in Vulvovaginal Candidiasis. The analyst notes that the data shows the 1-day 300mg BID SCY-078 is "at least equivalent and likely more effective" than the standard 150mg single dose of fluconazole made by Pfizer (PFE). Carr adds that the gastrointestinal tolerability of SCY-078 is also acceptable, which was a key concern in the earlier Phase 2a trial. The analyst further states that the new valuation accounts for expected commercialization of the drug in VVC amid a likely strong interest in a new oral agent suggested by his ObGyn survey last month.
07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
06/28/18
WELS
06/28/18
NO CHANGE
WELS
Wells says Amazon deal, Walgreens results have negative read for drug pricing
After Amazon (AMZN) agreed to acquire online pharmacy PillPack, reportedly for $1B, Wells Fargo analyst David Maris noted that he has long stated that Amazon would enter the pharmacy business and warned about the risk to drug pricing in such a scenario. Maris also noted that Walgreens (WBA) reported its U.S. retail pharmacy comparable store sales fell 1.2% in Q3, adding that retailers tend to push drugmakers on price when they feel pressure and the read-through from its report may be negative for drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
AUY Yamana Gold
$2.90

-0.01 (-0.34%)

05/03/18
MITR
05/03/18
UPGRADE
MITR
Buy
Yamana Gold upgraded to Buy from Hold at GMP Securities
04/10/18
NATB
04/10/18
UPGRADE
NATB
Outperform
Yamana Gold upgraded to Outperform from Sector Perform at National Bank
02/09/18
MACQ
02/09/18
UPGRADE
MACQ
Outperform
Yamana Gold upgraded to Outperform from Neutral at Macquarie
01/26/18
FBCO
01/26/18
UPGRADE
Target $4.25
FBCO
Outperform
Yamana Gold upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Anita Soni upgraded Yamana Gold to Outperform and raised his price target for the shares to $4.25 from $3.50. The analyst believes the company will announce better than expected guidance and has a positive view on the proposed Brio deal.
TSLA Tesla
$316.75

-1.55 (-0.49%)

07/03/18
NOMU
07/03/18
NO CHANGE
Target $450
NOMU
Buy
Tesla reestablished some credibility yesterday, says Nomura Instinet
Tesla yesterday confirmed that it hit its production target of 5,000 Model 3's in the final week of the quarter, an important milestone that reestablishes some credibility and positions the company for profitability in the second half of the year, Nomura Instinet analyst Romit Shah tells investors in a research note. The analyst, however, continues to expect Tesla shares to be volatile near term. He sees the current weakness as an opportunity to further accumulate shares and keeps a Buy rating on the name with a $450 price target. Tesla closed yesterday down $7.88 to $335.07.
07/11/18
BOFA
07/11/18
NO CHANGE
Target $180
BOFA
Buy
Tesla sees 5k per week production level as sustainable, says BofA/Merrill
BofA/Merrill analyst John Murphy kept his Buy rating and $180 price target on Tesla after hosting investor meetings with its management which included the Senior Director of Investor Relations Aaron Chews. Murphy says their presentation indicates that not only is the 5K vehicle output per week level sustainable, the company is on its way to building over 6K cars per week by Q3 and 10K per week by mid-2019. The analyst notes however that he is a bit skeptical about that forecast and believes that it will take "some time" before Model 3 output can reach "material scale". Murphy further states that Tesla's announced agreement with Shanghai government to build a factory in the region comes with an opportunity for production capacity expansion as well as a risk around funding with operating cash flows and higher prices due to U.S.-China trade friction.
07/03/18
GSCO
07/03/18
NO CHANGE
GSCO
Sell
Tesla demand data point a concern, says Goldman Sachs
Goldman Sachs analyst David Tamberrino notes that while Tesla did achieve its 5k/week production target for the Model 3, the company's Model 3 deliveries did miss the analyst's bearish estimates. Further, he sees the incremental color on Model 3 net reservations where the company showed its first declining data point as incrementally negative. Tamberrino reiterates a Sell rating on the shares.
07/10/18
KEYB
07/10/18
NO CHANGE
KEYB
Sector Weight
Tesla production potential a chance to talk bull case, says KeyBanc
After Bloomberg reported that Tesla is expected to to sign a memorandum of understanding in Shanghai to build a plant in China capable of producing 500,000 vehicle per year, KeyBanc analyst Brad Erickson told investors in a research note that "this is just the kind of announcement and scenario contemplated" in his positive near-term bias, whereby he thinks investors would attribute some incremental value associated with the incremental production well ahead of revenue. Erickson believes the company's formal messaging of China production will come before the company showing more meaningful steps toward Model 3 profitability, as a China factory will likely require an incremental capital raise. The analyst, who has a Sector Weight rating on Tesla shares, sees Tesla delivering about 426,000 vehicles at an average selling price of about $57,600 in 2020, while doing an additional $4.3B in battery revenue at an operating margin of 8%.
XHB SPDR Homebuilders
$40.49

0.14 (0.35%)

TODAY'S FREE FLY STORIES

CL

Colgate-Palmolive

$62.80

0.26 (0.42%)

10:50
10/15/18
10/15
10:50
10/15/18
10:50
Options
Put sales in Colgate as implied volatility reaches 52-week highs »

Put sales in Colgate as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVU

Supervalu

$32.47

-0.005 (-0.02%)

, UNFI

United Natural Foods

$26.62

-0.52 (-1.92%)

10:49
10/15/18
10/15
10:49
10/15/18
10:49
Earnings
Supervalu reports Q2 EPS ($1.49), may not compare to consensus 37c »

Reports Q2 revenue…

SVU

Supervalu

$32.47

-0.005 (-0.02%)

UNFI

United Natural Foods

$26.62

-0.52 (-1.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

10:45
10/15/18
10/15
10:45
10/15/18
10:45
General news
Breaking General news story  »

8-Week Bill Announcement…

10:45
10/15/18
10/15
10:45
10/15/18
10:45
General news
Breaking General news story  »

4-Week Bill Announcement…

AAPL

Apple

$219.33

-2.77 (-1.25%)

10:42
10/15/18
10/15
10:42
10/15/18
10:42
Periodicals
Kuo says 2019 iPhones to have same water resistance as iPhone XS, MacRumors says »

Apple analyst Ming-Chi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAL

American Airlines

$31.54

0.63 (2.04%)

10:40
10/15/18
10/15
10:40
10/15/18
10:40
Options
American Airlines calls active with shares seeing relative strength »

American Airlines calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

10:40
10/15/18
10/15
10:40
10/15/18
10:40
General news
Treasury Action: Treasury introduces its new 8-week bill today »

Treasury Action: Treasury…

10:39
10/15/18
10/15
10:39
10/15/18
10:39
Conference/Events
RBC Capital restaurants/food analyst to hold analyst/industry conference call »

Consumer/Food &…

AZN

AstraZeneca

$37.30

0.15 (0.40%)

10:37
10/15/18
10/15
10:37
10/15/18
10:37
Periodicals
AstraZeneca suspends investments in Britain due to Brexit, Reuters reports »

AstraZeneca has halted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 23

    Oct

  • 07

    Nov

BAC

Bank of America

$27.83

-0.595 (-2.09%)

10:35
10/15/18
10/15
10:35
10/15/18
10:35
Hot Stocks
Bank of America reports September card write-offs 2.59% vs. 2.75% last month »

Reports September 30-plus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 24

    Oct

EVA

Enviva

$30.82

0.32 (1.05%)

10:35
10/15/18
10/15
10:35
10/15/18
10:35
Hot Stocks
Enviva: Facilities incured 'limited' damage from Hurricane Michael »

Enviva Partners reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMNY

Helios and Matheson

$0.02

0.0001 (0.58%)

10:33
10/15/18
10/15
10:33
10/15/18
10:33
Hot Stocks
Helios and Matheson: Proxy firms recommend voting for reverse stock split »

Helios and Matheson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:30
10/15/18
10/15
10:30
10/15/18
10:30
Conference/Events
RBC Capital healthcare tech analyst to hold analyst/industry conference call »

Healthcare Technology…

PFE

Pfizer

$43.13

-0.65 (-1.48%)

10:30
10/15/18
10/15
10:30
10/15/18
10:30
Options
Pfizer call option buyers as shares slip »

Pfizer call option buyers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 19

    Oct

  • 19

    Oct

  • 22

    Oct

  • 30

    Oct

  • 07

    Nov

10:30
10/15/18
10/15
10:30
10/15/18
10:30
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

CAMP

CalAmp

$19.42

-0.02 (-0.10%)

, EB

Eventbrite

$27.95

-0.17 (-0.60%)

10:29
10/15/18
10/15
10:29
10/15/18
10:29
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…

CAMP

CalAmp

$19.42

-0.02 (-0.10%)

EB

Eventbrite

$27.95

-0.17 (-0.60%)

XYF

X Financial

$9.10

-0.45 (-4.71%)

BSVN

Bank7

$18.47

0.35 (1.93%)

ELAN

Elanco

$31.90

-0.76 (-2.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

PH

Parker-Hannifin

$163.81

-3.6 (-2.15%)

, ROK

Rockwell Automation

$170.00

-2.89 (-1.67%)

10:29
10/15/18
10/15
10:29
10/15/18
10:29
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…

PH

Parker-Hannifin

$163.81

-3.6 (-2.15%)

ROK

Rockwell Automation

$170.00

-2.89 (-1.67%)

NTRI

Nutrisystem

$34.46

-2.66 (-7.17%)

KLAC

KLA-Tencor

$91.27

-1.91 (-2.05%)

DLPH

Delphi Technologies

$23.27

-0.09 (-0.39%)

MNST

Monster Beverage

$52.46

-0.83 (-1.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$164.45

0.63 (0.38%)

, PNC

PNC Financial

$124.75

0.6 (0.48%)

10:29
10/15/18
10/15
10:29
10/15/18
10:29
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…

MCD

McDonald's

$164.45

0.63 (0.38%)

PNC

PNC Financial

$124.75

0.6 (0.48%)

RL

Ralph Lauren

$124.99

3.5 (2.88%)

ATVI

Activision Blizzard

$75.00

-2.99 (-3.83%)

LULU

Lululemon

$144.33

0.63 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 23

    Oct

  • 06

    Nov

  • 16

    Jan

  • 12

    Apr

  • 17

    Jul

  • 16

    Oct

HMLP

Hoegh LNG Partners

$17.82

0.155 (0.88%)

10:29
10/15/18
10/15
10:29
10/15/18
10:29
Hot Stocks
Breaking Hot Stocks news story on Hoegh LNG Partners 

Hoegh LNG trading resumes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$332.99

5.51 (1.68%)

10:26
10/15/18
10/15
10:26
10/15/18
10:26
Periodicals
Lockheed Martin's F-35 flights resume after examination, Reuters reports »

F-35 jets have resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 30

    Oct

AMZN

Amazon.com

$1,747.72

-40.91 (-2.29%)

10:26
10/15/18
10/15
10:26
10/15/18
10:26
Technical Analysis
Technical Take: Amazon.com poised for a bounce »

The stock was last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 25

    Oct

NBEV

New Age Beverages

$6.62

0.43 (6.95%)

10:25
10/15/18
10/15
10:25
10/15/18
10:25
Options
New Age Beverages call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:25
10/15/18
10/15
10:25
10/15/18
10:25
Conference/Events
Cowen pharmaceuticals analyst to hold an analyst/industry conference call »

Pharmaceuticals Analyst…

IHRT

iHeartMedia

$0.00

(0.00%)

10:25
10/15/18
10/15
10:25
10/15/18
10:25
Conference/Events
Cowen TMT analyst Vitanza to hold an analyst/industry conference call »

Technology, Media and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

PBYI

Puma Biotechnology

$42.19

-0.5 (-1.17%)

, RHHBY

Roche

$0.00

(0.00%)

10:20
10/15/18
10/15
10:20
10/15/18
10:20
Recommendations
Puma Biotechnology, Roche analyst commentary  »

Roche breast cancer data…

PBYI

Puma Biotechnology

$42.19

-0.5 (-1.17%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 19

    Oct

  • 07

    Nov

  • 24

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.